Canagliflozin hemihydrate

Research use only, not for human use.

Canagliflozin hemihydrate (TA 7284) is a drug of the gliflozin class or subtype 2 sodium-glucose transport inhibitors used for the treatment of type 2 diabetes.

Canagliflozin hemihydrate (JNJ28431754 hemihydrate) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.

Canagliflozin inhibits Na+-dependent 14C-AMG uptake in CHO-hSGLT2 cells, with an IC50 of 4.4±1.2 nM. Similar IC50 values are obtained in CHO-rSGLT2 and CHO-mSGLT2 cells (IC50?=?3.7 and 2.0 nM for rat and mouse SGLT2, respectively). Canagliflozin inhibits 14C-AMG uptake in CHO-hSGLT1 and mSGLT1 cells with IC50 of 684±159 nM and >1,000 nM, respectively.

Canagliflozin (30 mg/kg treatment for 4 weeks) reduces blood glucose (BG) levels, respiratory exchange ratio, and body weight gain in DIO mice.Canagliflozin (3 mg/kg for 3 weeks) increases urinary glucose excretion (UGE) with no significant change in total food intake compared with that in vehicle-treated rats, leading to a decrease in body weight In ZF rats.Animal Model:Diet-induced obese, insulin resistantmice (DIO) Mice Dosage:30 mg/kg Administration:Oral gavage; daily; 4 weeks Result:Reduced BG levels, respiratory exchange ratio, and body weight gain.Animal Model:Male Zucker fatty (ZF) obese, insulin resistant ratsDosage:3 mg/kg Administration:Oral gavage; daily; 3 weeks Result:UGE was increased with no significant change in total food intake compared with that in vehicle-treated rats, leading to a decrease in body weight.

——

GPCR/G Protein

SGLT

SGLT

——

——

928672-86-0

907.05

C48H52F2O11S2

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (220.50 mM)

O[C@H]1[C@H](C2=CC(CC3=CC=C(C4=CC=C(C=C4)F)S3)=C(C=C2)C)O[C@@H]([C@H]([C@@H]1O)O)CO.O[C@H]5[C@H](C6=CC(CC7=CC=C(C8=CC=C(C=C8)F)S7)=C(C=C6)C)O[C@@H]([C@H]([C@@H]5O)O)CO.O

——

(-20℃)

With Ice Pack

≥ 2 years